Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Junkyardawg who wrote (15829)	3/8/1999
From: Glenn	Read Replies (2) \| Respond to of 90042

The statement was a watch statement. Ericsson has made overtures to the effect that it is going into buy mode. Fore is a candidate. No buy recommendation. Just a strong push to do some homework here. Glenn

To: Junkyardawg who wrote (15829)	3/8/1999 1:43:00 PM
From: Junkyardawg	Read Replies (2) \| Respond to of 90042

Out of SFA very small loss. (commisions) In VVUS @ 4 The sky is limit for this one. I sold this morning at 2 1/4 and just bought back in a 4 A mistake but I will move on. Check out the news on this baby. Female Sexual Dysfunction Patent Granted to VIVUS; VIVUS Plans Diversification of R&D MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 8, 1999--VIVUS, Inc. (Nasdaq:VVUS) has been issued patent no. 5877216 for the "Treatment of Female Sexual Dysfunction" by the U.S. Patent Office. This patent provides VIVUS with broad protection for the commercialization of topical formulations of vasodilating agents and steroid hormones for the treatment of sexual dysfunctions effecting women. Therapeutic opportunities include treatments for women with arousal and orgasm dysfunction, the enhancement of vaginal lubrication, and the improvement of vaginal muscle tone. "This important patent underscores VIVUS' commitment to diversify its research and development efforts within urology beyond the treatment of male erectile dysfunction," stated Leland Wilson, President and CEO of VIVUS, Inc. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). CONTACT: VIVUS, Inc. Nina W. Ferrari, 650/934-5200 IR@VIVUS.com